Agile Therapeutics Inc COM PAR $0.0001 Stock (OTC: AGRX)

Agile Therapeutics Inc COM PAR $0.0001 (OTC:AGRX) Stock, Quote.Headers.trade-ideas

Agile Therapeutics

stock-1863880

News

AGRX

Agile Therapeutics shares are trading lower by 61% during Tuesday&#39;s session. The company announced the suspension of its trading on the Nasdaq effective Tuesday.

Why Agile Therapeutics (AGRX) Stock Is Down 60%

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACVA

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

ATNI

BBLG

BELFA

BZFD

DOCN

DPRO

EAST

ETSY

EZFL

GBNH

GSHD

INDV

KTOS

LCID

LNTH

LRHC

LUNG

MATV

MGPI

MNPR

MNTS

NOVA

NVAX

NVDA

OCUL

QTWO

RELY

RILY

RIVN

ROOT

RXRX

SMCI

SNPS

SNPX

TRUE

VERO

Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Health insurance

Health Care

Financing

Agile Therapeutics stock rises on premarket trading, exercising warrants for $4.8M gross proceeds with reduced exercise price of $1.25 per share.

What&#39;s Going On With Women Health Focused Agile Therapeutics Stock Today?

Agile Therapeutics Inc COM PAR $0.0001

Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.51) by 23.53 percent. The company reported quarterly sales of $5.72 million which beat the analyst consensus estimate of $3.75 million by 52.35 percent. This is a 49.91 percent increase over sales of $3.81 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Agile Therapeutics Q1 2024 Adj EPS $(0.63) Misses $(0.51) Estimate, Sales $5.72M Beat $3.75M Estimate

Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(0.92) by 58.7 percent. This is a 83.78 percent increase over losses of $(9.00) per share from the same period last year. The company reported quarterly sales of $3.62 million which missed the analyst consensus estimate of $4.07 million by 11.18 percent. This is a 9.53 percent decrease over sales of $4.00 million the same period last year.

Agile Therapeutics Q4 Adj $(1.46) Misses $(0.92) Estimate, Sales $3.62M Miss $4.07M Estimate

Agile Therapeutics (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#OTC">AGRX</a>) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:05 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Agile Therapeutics missed estimated earnings by -59.0%, reporting an EPS of $-1.46 versus an estimate of $-0.92.
Revenue was down $381 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.37 which was followed by a 2.0% drop in the share price the next day.
Here's a look at Agile Therapeutics's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.84</td>
<td>-3.48</td>
<td>-7.50</td>
<td>-11.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.47</td>
<td>-3.10</td>
<td>-7.76</td>
<td>-9</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>5.27M</td>
<td>4.68M</td>
<td>3.40M</td>
<td>3.08M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>6.66M</td>
<td>5.50M</td>
<td>3.81M</td>
<td>4.00M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Agile Therapeutics <a href="https://www.benzinga.com/quote/AGRX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Agile Therapeutics: Q4 Earnings Insights

Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) is set to give its latest quarterly earnings report on Thursday, 2024-03-28. Here's what investors need to know before the announcement.
Analysts estimate that Agile Therapeutics will report an earnings per share (EPS) of $-0.92. 
Agile Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.37, which was followed by a 2.44% drop in the share price the next day.
Here's a look at Agile Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.84</td>
<td>-3.48</td>
<td>-7.50</td>
<td>-11.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.47</td>
<td>-3.10</td>
<td>-7.76</td>
<td>-9</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-2.0%</td>
<td>-12.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711548053_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Agile Therapeutics were trading at $0.334 as of March 22. Over the last 52-week period, shares are down 96.87%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AGRX/earnings">To track all earnings releases for Agile Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Agile Therapeutics's Earnings: A Preview

Agile Therapeutics Inc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#OTC">AGRX</a>) shares are trading lower by 61% to $0.24 during Tuesday&#8217;s session after the company announced the suspension of its trading on the Nasdaq <a href="https://www.benzinga.com/pressreleases/24/03/g37923070/agile-therapeutics-announces-delisting-from-nasdaq">effective Tuesday</a>. The company received a final delisting notice from Nasdaq due to its failure to meet the minimum stockholders&#8217; equity requirement. 
As a result, trading of its common stock on Nasdaq was suspended effective March 26. However, the company&#8217;s shares will still be publicly traded on the over-the-counter market operated by the OTC Markets Group Inc. under the symbol AGRX. 
Agile Therapeutics added and emphasized that this transition will not impact its business operations and reaffirms its commitment to executing its business plan and exploring strategic opportunities to enhance Twirla growth and shareholder value.
See Also: <a href="https://www.benzinga.com/markets/equities/24/03/37934317/is-donald-trumps-truth-socials-public-debut-worth-the-hype-experts-urge-caution">Is Donald Trump&#8217;s Truth Social&#8217;s Public Debut Worth The Hype? Expert Urges Caution</a>
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AGRX has a 52-week high of $12.25 and a 52-week low of $0.20.

<h3>Gainers</h3>
<ul>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) shares increased by 77.7% to $11.55 during Monday's after-market session. The company's market cap stands at $515.7 million. As per the news, the Q4 earnings report came out today. </li>
<li>OpGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPGN#NASDAQ">OPGN</a>) shares moved upwards by 66.61% to $0.79. The market value of their outstanding shares is at $7.9 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 11.62% to $1.92. The company's market cap stands at $7.0 million. </li>
<li>Vaxxinity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAXX#NASDAQ">VAXX</a>) shares moved upwards by 7.99% to $0.72. The company's market cap stands at $90.8 million. </li>
<li>Unity Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBX#NASDAQ">UBX</a>) stock rose 7.39% to $1.7. The market value of their outstanding shares is at $28.4 million. </li>
<li>Brainstorm Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCLI#NASDAQ">BCLI</a>) stock increased by 6.87% to $0.7. The market value of their outstanding shares is at $34.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) shares declined by 54.7% to $0.27 during Monday's after-market session. </li>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock decreased by 54.53% to $0.45. The market value of their outstanding shares is at $1.6 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock declined by 6.73% to $0.48. The market value of their outstanding shares is at $9.4 million. </li>
<li>Omeros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) shares decreased by 6.69% to $3.21. The company's market cap stands at $201.7 million. </li>
<li>BIMI Intl Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) shares decreased by 6.46% to $1.73. The company's market cap stands at $24.2 million. </li>
<li>Regenxbio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGNX#NASDAQ">RGNX</a>) stock decreased by 5.15% to $20.48. The company's market cap stands at $1.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BCLI

BIMI

NBSE

OMER

OPGN

PRTG

RGNX

STOK

VAXX

12 Health Care Stocks Moving In Monday's After-Market Session

WIIM

Agile Therapeutics shares are trading lower after the company announced suspension of its trading on the Nasdaq will be effective Mar. 26.

Suspension of trading in the Company&#39;s common stock on the Nasdaq exchange will be effective at the open of trading on March 26, 2024.&nbsp;Effective March 26, 2024, the Company&#39;s common stock will be eligible for quotation and trading on the &quot;over the counter&quot; market operated by the&nbsp;OTC Markets Group Inc.&nbsp;(the &quot;OTC Market&quot;).&nbsp;

Agile Therapeutics Reveals Final Delisting Notice From Nasdaq

<h3>Companies Reporting Before The Bell</h3>
&bull; Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) is likely to report quarterly loss at $0.54 per share on revenue of $9.20 million.
&bull; 51 Talk Online Education (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COE#AMEX">COE</a>) is projected to report earnings for its fourth quarter.
&bull; Star Equity Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRR#NASDAQ">STRR</a>) is likely to report quarterly loss at $0.08 per share on revenue of $9.15 million.
&bull; Hyzon Motors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYZN#NASDAQ">HYZN</a>) is likely to report earnings for its fourth quarter.
&bull; Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) is estimated to report quarterly loss at $0.24 per share on revenue of $60 thousand.
&bull; AstroNova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALOT#NASDAQ">ALOT</a>) is likely to report earnings for its fourth quarter.
&bull; Sunlands Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STG#NYSE">STG</a>) is likely to report earnings for its fourth quarter.
<h3>Companies Reporting After The Bell</h3>
&bull; Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) is estimated to report earnings for its fourth quarter.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ALOT

HUMA

HYZN

MBRX

STRR

Earnings Scheduled For March 22, 2024

Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) is set to give its latest quarterly earnings report on Friday, 2024-03-22. Here's what investors need to know before the announcement.
Analysts estimate that Agile Therapeutics will report an earnings per share (EPS) of $-0.54. 
Agile Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company beat EPS by $0.37, which was followed by a 2.44% drop in the share price the next day.
Here's a look at Agile Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.84</td>
<td>-3.48</td>
<td>-7.50</td>
<td>-11.5</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.47</td>
<td>-3.10</td>
<td>-7.76</td>
<td>-9</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-2.0%</td>
<td>-12.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711029612_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Agile Therapeutics were trading at $0.579 as of March 20. Over the last 52-week period, shares are down 95.04%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/AGRX/earnings">To track all earnings releases for Agile Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Maxim Group analyst Naz Rahman downgrades Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) from Buy to Hold.

Downgrades

Analyst Ratings

Maxim Group Downgrades Agile Therapeutics to Hold

Agile Therapeutics shares are trading higher after the company announced it has paid-off the remainder of its debt facility with Perceptive Advisors.

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. The market value of their outstanding shares is at $42.7 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) stock moved upwards by 25.0% to $0.1. The market value of their outstanding shares is at $4.0 million. </li>
<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) stock moved upwards by 19.34% to $0.87. The company's market cap stands at $2.5 million. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) stock moved upwards by 14.97% to $2.38. The company's market cap stands at $303.4 million. </li>
<li>HUTCHMED (China) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCM#NASDAQ">HCM</a>) stock increased by 14.04% to $18.62. The company's market cap stands at $3.1 billion. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLI#NASDAQ">QLI</a>) shares rose 13.14% to $0.62. The market value of their outstanding shares is at $22.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>P3 Health Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PIII#NASDAQ">PIII</a>) shares decreased by 14.7% to $0.87 during Wednesday's pre-market session. The market value of their outstanding shares is at $100.2 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) shares fell 12.69% to $3.51. The market value of their outstanding shares is at $2.5 million. </li>
<li>CryoPort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYRX#NASDAQ">CYRX</a>) shares decreased by 10.39% to $14.61. The market value of their outstanding shares is at $715.2 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock fell 9.9% to $0.82. The company's market cap stands at $40.9 million. </li>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares declined by 8.57% to $5.39. The market value of their outstanding shares is at $117.4 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares fell 8.21% to $0.04. The company's market cap stands at $1.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

CELU

CMPX

CYRX

Kintara Therapeutics, Inc. - Common Stock

KTRA

NCNA

PIII

RNLX

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Biotech

General

Agile Therapeutics Announced That It Has Paid-off The Remainder Of Its Debt Facility With Perceptive Advisors. The Company Remains Focused On Growing Twirla And Advancing The Company's Business Plan

<a href="https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/" title="https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/">https://www.washingtonpost.com/world/2024/03/04/france-abortion-constitution/</a>

Politics

DARE

EVFM

TEVA

'France becomes first country to explicitly enshrine abortion rights in constitution' -Washington Post Report

Shares of Etsy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etsy#NASDAQ">ETSY</a>) fell sharply during Thursday&rsquo;s session after the company reported <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37261895/4-etsy-analysts-stand-firm-on-ratings-post-q4-earnings-point-to-buyer-growth-fee-ex">mixed fourth-quarter financial results.</a>
Etsy reported quarterly earnings of 62 cents per share which missed the analyst consensus estimate of 78 cents. The company reported quarterly sales of $842.3 million, beating the analyst consensus estimate of $827.81 million. 
Etsy shares dipped 7.5% to $71.34 on Thursday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>La Rosa Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lrhc#NASDAQ">LRHC</a>) shares jumped 160.7% to $3.6499 after the company said it has acquired a 100% interest in the Company&#39;s franchisee - La Rosa Realty Winter Garden LLC located in Winter Garden, Florida.</li>
<li>BuzzFeed, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bzfd#NASDAQ">BZFD</a>) jumped 91.4% to $0.4150 after the company revealed the sale of Complex Networks to NTWRK, a live-streaming video commerce platform. The deal, valued at $108.6 million, will also result in a 16% reduction in BuzzFeed&rsquo;s workforce.</li>
<li>Monopar Therapeutics Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnpr#NASDAQ">MNPR</a>) rose 80.7% to $1.03 after the company disclosed promising preclinical data for its MNPR-101 radiopharma program targeting advanced cancers.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) shares gained 40.8% to $12.21 after posting better-than-expected fourth-quarter results.</li>
<li>Novavax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvax#NASDAQ">NVAX</a>) jumped 34.7% to $5.36. Novavax has reached a settlement related to the 2021 advance purchase agreement for Novavax&#39;s prototype Covid-19 vaccine (NVX-COV2373).</li>
<li>EZFill Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ezfl#NASDAQ">EZFL</a>) rose 34.3% to $1.86. EzFill announced preliminary 2023 revenues of $23 million, up 54% year over year.</li>
<li>Mercurity Fintech Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mfh#NASDAQ">MFH</a>) jumped 30% to $2.93.</li>
<li>Mativ Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/matv#NYSE">MATV</a>) gained 27.6% to $15.00 following upbeat earnings.</li>
<li>Venus Concept Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vero#NASDAQ">VERO</a>) shares climbed 26.9% to $1.6242 after the company received CE Mark from DEKRA Certification B.V. to market Venus Versa Pro in Europe.</li>
<li>Outset Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/om#NASDAQ">OM</a>) gained 26% to $4.0680 following upbeat results.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocul#NASDAQ">OCUL</a>) rose 22.2% to $9.19 after announcing a $325.0 million private placement.</li>
<li>Remitly Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rely#NASDAQ">RELY</a>) shares rose 19.5% to $21.13 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) gained 19.3% to $18.13. B. Riley&rsquo;s board issued a statement regarding internal review.</li>
<li>Super Micro Computer, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smci#NASDAQ">SMCI</a>) jumped 19.2% to $875.07. Supermicro announced a proposed offering of $1.5 billion of convertible senior notes due 2029.</li>
<li>Bone Biologics Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bblg#NASDAQ">BBLG</a>) gained 18.4% to $3.73.</li>
<li>Amylyx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amlx#NASDAQ">AMLX</a>) rose 17.5% to $18.00 following strong sales results.</li>
<li>ACV Auctions Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acva#NASDAQ">ACVA</a>) gained 16.9% to $16.37 after the company reported better-than-expected fourth-quarter financial results and announced the settlement of its antitrust litigation related to the AutoIMS technology platform.</li>
<li>FTI Consulting, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fcn#NYSE">FCN</a>) jumped 15.5% to $219.72 following upbeat results.</li>
<li>NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) rose 15.4% to $778.61 after the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for the first quarter.</li>
<li>OUTFRONT Media Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/out#NYSE">OUT</a>) gained 15.4% to $14.35 following upbeat results.</li>
<li>Lantheus Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lnth#NASDAQ">LNTH</a>) rose 14.4% to $64.90 following strong results.</li>
<li>Enerplus Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/erf#NYSE">ERF</a>) rose 13.7% to $18.67.</li>
<li>Indivior PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indv#NASDAQ">INDV</a>) gained 13.3% to $19.83 following fourth-quarter results.</li>
<li>Recursion Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rxrx#NASDAQ">RXRX</a>) rose 12.2% to $13.88.</li>
<li>Agile Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agrx#NASDAQ">AGRX</a>) gained 11.1% to $1.10. Agile Therapeutics was granted extension by Nasdaq Hearings Panel to regain compliance until March 25, 2024. The company sees FY23 revenue of $20 million to $21 million. Agile Therapeutics announces exercise of warrants for $4.8 million gross proceeds.</li>
<li>Synopsys, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snps#NASDAQ">SNPS</a>) gained 10.7% to $601.93 after the company reported better-than-expected first-quarter adjusted EPS results and issued strong guidance.</li>
<li>Q2 Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qtwo#NASDAQ">QTWO</a>) rose 9.5% to $45.82 following strong results.</li>
<li>Eastside Distilling, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/east#NASDAQ">EAST</a>) shares rose 7.6% to $1.0340.</li>
<li>DigitalOcean Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/docn#NYSE">DOCN</a>) gained 6.8% to $38.29 following upbeat results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Draganfly Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dpro#NASDAQ">DPRO</a>) shares fell 50.3% to $0.1790 after the company announced pricing of $3.6 million underwritten public offering.</li>
<li>Greenbrook TMS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbnh#NASDAQ">GBNH</a>) fell 46.6% to $0.2024 after the company announced a $1.2 million registered direct offering of 6 million shares at $0.20 per share purchase price.</li>
<li>Synaptogenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpx#NASDAQ">SNPX</a>) shares fell 29.5% to $0.1839 after surging 29% on Wednesday. Synaptogenix received a Notice of Allowance for its U.S. Patent application 17/665,033 titled &quot;Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases.&quot;</li>
<li>Rivian Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>) fell 26.8% to $11.25 after the company reported a wider-than-expected loss for its fourth quarter and announced plans to reduce its salaried workforce by around 10% to help further improve costs. The company said it sees production of 57,000 vehicles in 2024.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) fell 23.2% to $1.0750.</li>
<li>Goosehead Insurance, Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gshd#NASDAQ">GSHD</a>) dipped 21.2% to $68.78 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Bel Fuse Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/belfa#NASDAQ">BELFA</a>) fell 20.1% to $59.16 after the company reported weak fourth-quarter financial results.</li>
<li>Lucid Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcid#NASDAQ">LCID</a>) shares fell 19.1% to $2.9912 after the company reported mixed fourth-quarter financial results and issued guidance.</li>
<li>Sunnova Energy International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nova#NYSE">NOVA</a>) dipped 18.6% to $9.52 after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>ATN International, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atni#NASDAQ">ATNI</a>) declined 18.1% to $29.20 after the company reported fourth-quarter financial results and issued guidance.</li>
<li>Pulmonx Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lung#NASDAQ">LUNG</a>) fell 17.6% to $11.94 after the company reported fourth-quarter financial results.</li>
<li>MGP Ingredients, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgpi#NASDAQ">MGPI</a>) declined 14.3% to $78.75 after the company reported fourth-quarter financial results.</li>
<li>Momentus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnts#NASDAQ">MNTS</a>) shares fell 13.1% to $0.5995 after declining around 7% on Wednesday.</li>
<li>Standard Motor Products, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smp#NYSE">SMP</a>) dipped 12.7% to $35.01 after the company reported worse-than-expected fourth-quarter financial results and issued guidance.</li>
<li>Teekay Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tk#NYSE">TK</a>) gained 12.4% to $7.21 after the company reported a year-over-year decrease in Q4 financial results.</li>
<li>TrueCar, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/true#NASDAQ">TRUE</a>) dipped 11% to $3.4450 following weak sales.</li>
<li>Kratos Defense &amp; Security Solutions, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktos#NASDAQ">KTOS</a>) fell 8% to $18.57. Kratos Defense &amp; Security Solutions announced a proposed public offering of $300 million of common stock.</li>
<li>Rogers Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rog#NYSE">ROG</a>) fell 6.8% to $108.29 following weak quarterly results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37262506/booking-holdings-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earni"> Booking Holdings Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call </a>

Why Etsy Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Agile Therapeutics Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) shares jumped during the trading session on Thursday on a solid volume session volume of 9.91 million, compared to an average volume of a mere 78.141K, as per the data from&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>.
Thursday, Agile Therapeutics agreed to immediately exercise certain outstanding warrants to purchase up to an aggregate of 3.89 million shares issued in July 2022 and May 2023, having an exercise price of $3.69 per share at a reduced&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/02/g37261121/agile-therapeutics-announces-exercise-of-warrants-for-4-8-million-gross-proceeds" rel="noreferrer noopener">exercise price of $1.25 per share</a>.&nbsp;
The gross proceeds are expected to be approximately $4.8 million before deducting placement agent fees and estimated offering expenses.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/02/37241489/first-lady-jill-biden-unveils-100m-in-federal-funding-to-support-r-d-watch-out-for-these-women-he" rel="noreferrer noopener">First Lady Jill Biden Unveils $100M In Federal Funding To Support R&amp;D &#8211; Watch Out for These Women Health Stocks</a>.
In consideration of the immediate exercise of the warrants for cash, the company will issue new unregistered warrants to purchase shares.
The new warrants will be exercisable for an aggregate of up to 7,785,144 shares at an exercise price of $1.00 per share and immediately exercisable upon issuance.&nbsp;
3,992,572 of the new warrants will have a term of five years from the issuance date, and 3,792,572 of the new warrants will have a term of eighteen months from the issuance date.
Price Action: AGRX shares are up 2.80% at 1.02 on the last check Thursday. During the premarket trading, the stock reached as high as $2.68.
Photo via Shutterstock

What's Going On With Women Health Focused Agile Therapeutics Stock Today?

Agile Therapeutics Announces Exercise of Warrants For $4.8M Gross Proceeds

<h3>Gainers</h3>
<ul>
<li>Agile Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGRX#NASDAQ">AGRX</a>) stock rose 82.4% to $1.81 during Thursday's pre-market session. The company's market cap stands at $5.3 million. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock rose 72.95% to $2.11. The market value of their outstanding shares is at $11.6 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock rose 71.91% to $0.98. The market value of their outstanding shares is at $14.5 million. </li>
<li>Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) shares increased by 21.27% to $9.12. The market value of their outstanding shares is at $1.0 billion. </li>
<li>Indivior (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) shares increased by 16.74% to $20.43. The market value of their outstanding shares is at $2.7 billion. As per the press release, Q4 earnings came out today. </li>
<li>Apyx Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APYX#NASDAQ">APYX</a>) shares increased by 15.3% to $2.33. The company's market cap stands at $80.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Synaptogenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPX#NASDAQ">SNPX</a>) shares fell 20.9% to $0.21 during Thursday's pre-market session. The market value of their outstanding shares is at $4.2 million. </li>
<li>Motus GI Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOTS#NASDAQ">MOTS</a>) shares declined by 18.19% to $0.9. The company's market cap stands at $1.3 million. </li>
<li>Chemomab Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMMB#NASDAQ">CMMB</a>) shares decreased by 9.69% to $0.61. The market value of their outstanding shares is at $6.8 million. </li>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares fell 8.86% to $0.32. The company's market cap stands at $24.5 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock decreased by 7.91% to $0.09. The market value of their outstanding shares is at $4.8 million. </li>
<li>Cadrenal Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVKD#NASDAQ">CVKD</a>) stock declined by 7.84% to $0.68. The market value of their outstanding shares is at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APYX

ATPC

Chemomab Therapeutics Ltd. - American Depositary Shares

CMMB

CPHI

CVKD

MOTS

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Shares of NVIDIA Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) rose sharply in today&rsquo;s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong revenue guidance for the first quarter.
The company reported revenue of $22.10 billion, beating a Street estimate of $20.62 billion. Revenue in the fourth quarter was up 265% year-over-year. Nvidia reported fourth-quarter non-GAAP earnings per share of $5.16, which came in ahead of a Street consensus estimate of $4.64 according to data from Benzinga Pro.
NVIDIA shares surged 14.3% to $771.50 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Agile Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/agrx#NASDAQ">AGRX</a>) gained 140.4% to $2.38 in pre-market trading. Agile Therapeutics was granted extension by Nasdaq Hearings Panel to regain compliance until March 25, 2024. The company sees FY23 revenue of $20 million to $21 million.</li>
<li>BuzzFeed, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bzfd#NASDAQ">BZFD</a>) shares surged 89.6% to $0.4145 in pre-market trading after the company revealed the sale of Complex Networks to NTWRK, a live-streaming video commerce platform. The deal, valued at $108.6 million, will also result in a 16% reduction in BuzzFeed&rsquo;s workforce.</li>
<li>Elevai Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/elab#NASDAQ">ELAB</a>) shares rose 57.4% to $1.21 in pre-market trading. Braeden Lichti reported a 22.07% stake in Elevai Labs.</li>
<li>GRI Bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gri#NASDAQ">GRI</a>) shares jumped 55% to $1.50 in pre-market trading. GRI Bio recently announced pricing of a $5.5 million public offering.</li>
<li>Eastside Distilling, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/east#NASDAQ">EAST</a>) shares rose 38% to $1.32 in pre-market trading.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) shares gained 24.4% to $10.78 in pre-market trading after posting better-than-expected fourth-quarter results.</li>
<li>Beamr Imaging Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmr#NASDAQ">BMR</a>) gained 21.7% to $12.34 in pre-market trading after dipping 18% on Wednesday.</li>
<li>Remitly Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rely#NASDAQ">RELY</a>) shares rose 21% to $21.40 in pre-market trading after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Indivior PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/indv#NASDAQ">INDV</a>) gained 16.7% to $20.43 in pre-market trading following fourth-quarter results.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Draganfly Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dpro#NASDAQ">DPRO</a>) fell 50.8% to $0.1770 in pre-market trading after the company announced pricing of $3.6 million underwritten public offering.</li>
<li>Synaptogenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpx#NASDAQ">SNPX</a>) shares fell 21.2% to $0.2093 in pre-market trading after surging 29% on Wednesday. Synaptogenix received a Notice of Allowance for its U.S. Patent application 17/665,033 titled &quot;Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases.&quot;</li>
<li>Bel Fuse Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/belfb#NASDAQ">BELFB</a>) dipped 20.1% to $55.99 in pre-market trading after posting weaker-than-expected quarterly results.</li>
<li>Greenbrook TMS Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gbnh#NASDAQ">GBNH</a>) shares fell 18.7% to $0.3110 after jumping 94% on Wednesday.</li>
<li>Momentus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnts#NASDAQ">MNTS</a>) shares dipped 18.3% to $0.5636 in pre-market trading after declining around 7% on Wednesday.</li>
<li>Visionary Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gv#NASDAQ">GV</a>) shares fell 15% to $0.17 in pre-market trading.</li>
<li>Rivian Automotive, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rivn#NASDAQ">RIVN</a>) fell 14.2% to $13.20 in pre-market trading after the company reported a wider-than-expected loss for its fourth quarter and announced plans to reduce its salaried workforce by around 10% to help further improve costs. The company said it sees production of 57,000 vehicles in 2024.</li>
<li>Energy Focus, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/efoi#NASDAQ">EFOI</a>) fell 12.7% to $2.00 in pre-market trading after gaining around 66% on Wednesday.</li>
<li>Etsy, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/etsy#NASDAQ">ETSY</a>) fell 11.3% to $68.44 in pre-market trading after the company reported mixed fourth-quarter financial results.</li>
<li>Lucid Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcid#NASDAQ">LCID</a>) shares fell 8.2% to $3.40 in pre-market trading after the company reported mixed fourth-quarter financial results and issued guidance.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/02/37253951/nvidia-keurig-dr-pepper-and-3-stocks-to-watch-heading-into-thursday"> NVIDIA, Keurig Dr Pepper And 3 Stocks To Watch Heading Into Thursday</a>

Pre-Market Outlook

BELFB

EFOI

ELAB

ALPS ETF Trusthen & Steers Global Realty Majors ETF

Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

The stock is down 13.51% to $0.32 after the report.The firm's lower revenue growth to earnings signals that the firm has been able to reduce costs and improve its profit margin overall.InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.Prior to the report, InvestorsObserver ga

Agile Therapeutics Inc Down 13.51% To $0.32 After Earnings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Agile Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/agrx-stock-quote/">AGRX</a>) just reported results for the fourth quarter of 2023.<ul><li>Agile Therapeutics reported earnings per share of -$1.46. This was below the analyst estimate for EPS of -92 cents.</li><li>The company reported revenue of $3.62 million.</li><li>This was 11.18% worse than the analyst estimate for revenue of $4.07 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/agrx-stock-earnings-agile-therapeutics-for-q4-of-2023/">AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AGRX Stock Earnings: Agile Therapeutics Misses EPS, Misses Revenue for Q4 2023

Agile Therapeutics (AGRX) has disclosed a new risk, in the Share Price & Shareholder Rights category. Agile Therapeutics faces significant business...

Agile Therapeutics' Balancing Act: Funding Challenges Threaten R&D and Twirla Rollout

Agile Therapeutics (AGRX) has provided an announcement. The latest update for investors is now available, including a refreshed corporate presentat...

Agile Therapeutics Releases Updated Investor Presentation

Agile Therapeutics Non-GAAP EPS of -$0.63, revenue of $5.7M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Agile Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/agrx-stock-quote/">AGRX</a>) just reported results for the first quarter of 2024.<ul><li>Agile Therapeutics reported earnings per share of -63 cents. This was below the analyst estimate for EPS of -51 cents.</li><li>The company reported revenue of $5.72 million.</li><li>This was 52.43% better than the analyst estimate for revenue of $3.75 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/agrx-stock-earnings-agile-therapeutics-for-q1-of-2024/">AGRX Stock Earnings: Agile Therapeutics Misses EPS, Beats Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AGRX Stock Earnings: Agile Therapeutics Misses EPS, Beats Revenue for Q1 2024

Agile Therapeutics to be acquired by Spain-based Insud for an enterprise value of ~$45M

Agile Therapeutics (AGRX) has provided an announcement. Agile Therapeutics, Inc. has entered into a merger agreement with Insud Pharma, S.L. and it...

Agile Therapeutics Merges with Insud Pharma Subsidiary

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Agile Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/agrx-stock-quote/">AGRX</a>) just reported results for the second quarter of 2024.<ul><li>Agile Therapeutics reported earnings per share of -$1.73.</li><li>The company reported revenue of $5.58 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/agrx-stock-earnings-agile-therapeutics-for-q2-of-2024/">AGRX Stock Earnings: Agile Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AGRX Stock Earnings: Agile Therapeutics Reported Results for Q2 2024

Agile Therapeutics (AGRX) has shared an update. Agile Therapeutics recently completed a significant merger, resulting in substantial changes to the...

Agile Therapeutics Embarks on New Chapter Post-Merger

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, TBNK, AGRX, UMBF on Behalf of Shareholders

AGILE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Agile Therapeutics, Inc. - AGRX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, SHCR, AGRX on Behalf of Shareholders

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INFN, SPR, AGRX, GRDI on Behalf of Shareholders

Kuehn Law Encourages AGRX, SPR, HCP, and ALLG Investors to Contact Law Firm

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Agile Therapeutics, Inc. - AGRX

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, DM, AGRX on Behalf of Shareholders

Kuehn Law Encourages AGRX, SPR, ENV, and UMBF Investors to Contact Law Firm

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENV, SPR, UMBF, AGRX on Behalf of Shareholders

Agile Therapeutics Inc. Announces Completion of Acquisition by Insud Pharma, S.L.

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Agile Therapeutics Inc COM PAR $0.0001

Agile Therapeutics Inc COM PAR $0.0001 (AGRX) Forecast

Agile Therapeutics Inc COM PAR $0.0001 (OTC:AGRX) Stock, Quote.Headers.trade-ideas